Larimar Therapeutics, Inc. (LRMR)
US — Healthcare Sector
Automate Your Wheel Strategy on LRMR
With Tiblio's Option Bot, you can configure your own wheel strategy including LRMR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LRMR
- Rev/Share 0.0038
- Book/Share 2.2555
- PB 0.9976
- Debt/Equity 0.0337
- CurrentRatio 7.4765
- ROIC -0.7116
- MktCap 144062775.0
- FreeCF/Share -1.3672
- PFCF -1.6473
- PE -1.5113
- Debt/Assets 0.0286
- DivYield 0
- ROE -0.5248
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LRMR | Truist | -- | Buy | -- | $18 | Jan. 29, 2025 |
| Initiation | LRMR | Oppenheimer | -- | Outperform | -- | $26 | Oct. 16, 2024 |
| Initiation | LRMR | Wedbush | -- | Outperform | -- | $22 | Oct. 3, 2024 |
| Initiation | LRMR | H.C. Wainwright | -- | Buy | -- | $15 | Oct. 2, 2024 |
News
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
LRMR
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BALA CYNWYD, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2024 operating and financial results.
Read More
About Larimar Therapeutics, Inc. (LRMR)
- IPO Date 2014-06-19
- Website https://www.larimartx.com
- Industry Biotechnology
- CEO Dr. Carole S. Ben-Maimon M.D.
- Employees 65
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.